Trade Name (Agent): Keytruda (pembrolizumab)
Sponsor: Merck Sharp & Dohme Corp
Date of BT Designation Disclosure: 7/01/2017
Approval Date: 12/19/2018
Indication: Adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
Category: Cancer